Clinical Nelson Study confirms: lung cancer screening saves lives

At the 19th World Conference on Lung Cancer, everyone was excited when Dr. De Koning presented the astonishing results of the Dutch-Belgian Lung Cancer Screening Trial NELSON.

The NELSON study results impressively show that low dose CT screening decreases mortality by 26% in asymptomatic men at high risk for lung cancer. For women, the prospects are even better: NELSON has shown a mortality reduction between 61% at 8 years and 39% at 10 years.

Following the US National Lung Screening Trial NLST, NELSON is the second largest trial that has given strong evidence for the benefits of low dose CT lung cancer screening programs. This is a giant step towards the introduction of lung cancer screening programs in the EU saving thousands of lives.

Veolity Supports Radiologists

MeVis Medical Solutions, the market leader in mammography screening software, offers Veolity: the software solution for effective lung screening reading available today.

Veolity supports the radiologist with its computer-aided detection (CAD) of lung nodules based on artificial intelligence, automatic nodule segmentation and volume measurements, streamlined current-prior workflow, advanced reporting in addition to other smart features and technology.

Veolity is available for Europe, the U.S., Canada, Australia, New Zealand and Republic of Korea.

For more details: Meet us at RSNA 2018 in Chicago, USA (South Building, booth no. 3929 Varex Imaging), visit www.veolity.com and contact our experts directly: sales(at)veolity.com.